Glioma diagnosis: Immunohistochemistry and beyond

Advances in Anatomic Pathology

Volumn 17, Issue 3, 2010, Pages 187-201

  Dunbar, Erin ^a   Yachnis, Anthony T ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

1p 19q; Diagnosis; EGFR; Glial neoplasm (glioma); MGMT; PTEN (chromosome 10)

Indexed keywords

EPIDERMAL GROWTH FACTOR; ERLOTINIB; GEFITINIB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ASTROCYTOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GENETICS; CELL INFILTRATION; CELL PROLIFERATION; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; GENE DELETION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MUTATIONAL ANALYSIS; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; TISSUE STRUCTURE;

BRAIN NEOPLASMS; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; TUMOR MARKERS, BIOLOGICAL;

EID: 77951758886     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3181d98cd9     Document Type: Review

References (96)

1. CBTRUS [http://www.cbtrus.org/reports/reports.html]. Central Brain Tumor Registry of the United States, 2009-2010.
2. Louis DN, Ohgaki H, Wiestler OD, et al. WHO Classification of Tumours of the Central Nervous System. Lyon: International Agency for Research; 2007.
3. Brat DJ, Prayson RA, Ryken TC, et al. Diagnosis of glioma: role of neuropathology. J Neurooncol. 2008;89:287-311.
4. Kleihues P, Cavenee WK. WHO Classification of Tumours: Pathology and Genetics-Tumors of the Nervous System. Lyon: International Agency for Research on Cancer; 2000.
5. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007;170:1445-1453.
6. Wen PY, Kesari S. Malignant gliomas in adults. N Engl JMed. 2008;359:492-507.
7. Homma T, Fukushima T, Vaccarella S, et al. Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol. 2006;9:846-854.
8. Kozak KR, Moody JS. Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis. Neurooncol. 2009;11:833-841.
9. Cosgrove MM, Rich KA, Kunin SA, et al. (1993) Keratin intermediate filament expression in astrocytic neoplasms: analysis by immunocytochemistry, western blot, and northern hybridization. Mod Pathol. 1993;6:342-347.
10. Oh D, Prayson RA. Evaluation of epithelial and keratin markers in glioblastoma multiforme: an immunohistochemical study. Arch Pathol Lab Med. 1999;123:917-920.
11. Peraud A, Watanabe K, Plate KH, et al. p53 mutations versus EGF receptor expression in giant cell glioblastomas. J Neuropathol Exp Neurol. 1997;56:1236-1241.
12. Meyer-Puttlitz B, Hayashi Y, Waha A, et al. Molecular genetic analysis of giant cell glioblastomas. Am J Pathol. 1997;151: 853-857.
13. Peraud A, Wantanabe K, Schwechheimer K, et al. Genetic profile of the giant cell glioblastoma. Lab Invest. 1999;79: 123-129.
14. Burger PC, Pearl DK, Aldape K, et al. Small cell architecture-a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol. 2001;60: 1099-1104.
15. Perry A, Aldape KD, George DH, et al. Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer. 2004;101:2318-2326.
16. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321: 1807-1812.
17. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-773.
18. Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116: 597-602.
19. Wantanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174:1149-1153.
20. Capper D,Weibert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010;20:245-254.
21. Kato Y, Jin G, Kuan C-T, et al. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Com. 2009;390: 547-551.
22. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27:4150-4154.
23. Horbinski C, Kofler J, Kelly LM, et al. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol. 2009;68:1319-1325.
24. Bar EE, Lin A, Tihan T, et al. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol. 2008;67:878-887.
25. Jones DTW, Kocialkowski S, Liu L, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68: 8673-8677.
26. Korshunov A, Golanov A, Sycheva R. Immunohistochemical markers for prognosis of cerebral glioblastomas. J Neurooncol. 2002;58:217-236. (Pubitemid 34830634)
27. Felsberg J, Rapp M, Loeser S, et al. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res. 2009;15:6683-6693.
28. Zolota V, Tsamandas AC, Aroukatos P, et al. Expression of cell cycle inhibitors p21, p27, p14 and p16 in gliomas. Correlation with classic prognostic factors and patients' outcome. Neuropathology. 2008;28:35-42.
29. Clark AJ, Dos Santos WG, McCready J, et al. Wilms tumor 1 expression in malignant gliomas and correlation of +KTS isoforms with p53 status. J Neurosurg. 2007;107: 586-592.
30. Schittenhelm J, Mittelbronn M, Nguyen TD, et al. WT1 expression distinguishes astrocytic tumor cells from normal and reactive astrocytes. Brain Pathol. 2008;18:344-353.
31. Bourne TD, Elias WJ, Mandell JW, et al. WT1 does not reliably distinguish reactive from neoplastic astrocytes. J Neuropathol Exp Neurol. 2009;69:582.
32. Bruner JM, Hair LS. Detection of abnormal p53 protein in progressive multifocalleukoencephalopathy. J Neuropathol Exp Neurol. 1993;52:271.
33. Lammie GA, Beckett A, Courtney R, et al. An immunohistochemical study of p53 and proliferating cell nuclear antigen expression in progressive multifocal leukoencephalopathy. Acta Neuropathol. 1994;88:465-471.
34. Ariza A, Mate JL, Fernandez-Vasalo A, et al. P53 and proliferating cell nuclear antigen expression in JC virus-infected cells of progressive multifocal leukoencephalopathy. Hum Pathol. 1994;25:1341-1345.
35. Giannini C, Scheithauer BW, Burger PC, et al. Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol. 1999;58:46-53.
36. Coons SW, Pearl DK. Mitosis identification in diffuse gliomas: implications for tumor grading. Cancer. 1998;82: 1550-1555.
37. Quinones-Hinojosa A, Sanai N, Smith JS, et al. Techniques to assess the proliferative potential of brain tumors. J Neurooncol. 2005;74:19-30.
38. Johannesen AL, Torp SH. The clinical value of Ki-67/MIB-1 labeling in human astrocytomas. Pathol Oncol Res. 2006;12: 143-147.
39. Hsu DW, Louis DN, Efird JT, et al. Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. J Neuropathol Exp Neurol. 1997;56:857-865.
40. Coons SW, Johnson PC. Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index. J Neuropathol Exp Neurol. 1993;52: 609-618.
41. McKeever PE, Ross DA, Strawderman MS, et al. An comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. J Neuropathol Exp Neurol. 1997;56:798-805.
42. Moskowitz SI, Jin T, Prayson RA. Role of MIB1 in predicting survival in patients with glioblastomas. J Neurooncol. 2006;76: 193-200.
43. Marie D, Liu Y, Moore SA, et al. Interobserver variability associated with the MIB-1 labeling index: high levels suggest limited prognostic usefulness for patients with primary brain tumors. Cancer. 2001;92:2720-2726.
44. Colman H, Giannini C, Huang L, et al. Assessment and prognostic significance of mitotic marker phopho-histone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol. 2006;30:657-664.
45. Lehman NL. Central nervous system tumors with ependymal features: a broadened spectrum of primarily ependymal differentiation? J Neuropathol Exp Neurol. 2008;67:177-188.
46. Min KW, Scheithauer BW. Clear cell ependymoma: a mimic of oligodendroglioma: clinicaopathological and ultrastructural considerations. Am J Surg Pathol. 1997;21:820-826.
47. Jain D, Sharma MC, Arora R, et al. Clear cell ependymoma: a mimicker of oligodendroglioma-report of three cases. Neuropathology. 2008;28:366-371.
48. Rodriguez FJ, Scheithauer BW, Perry A, et al. Ependymal tumors with sarcomatous change ("ependymosarcoma"): a clinicaopathologic and molecular cytogenetic study. Am J Surg Pathol. 2008;32:699-709.
49. Rodriguez FJ, Scheithauer BW, Robbins PD, et al. Ependymomas with neuronal differentiation: a morphologic and immunohistochemical spectrum. Acta Neuropathol. 2007;113: 313-324.
50. Bonnin JM, Rubinstein LJ. Astroblastomas: a pathological study of 23 tumors, with post-operative follow-up in 13 patients. Neurosurgery. 1989;25:6-13.
51. Brat DJ, Hirose Y, Cohen KJ, et al. Astroblastoma: clinicopathologic features and chromosomal abnormalities defined by comparative genomic hybridization. Brain Pathol. 2000;10: 342-352.
52. Mangano FT, Bradford AC, Mittler MA, et al. Astroblastoma. Case report, review of the literature, and analysis of treatment strategies. J Neurosurg Sci. 2007;51:21-27.
53. Wang M, Tihan T, Rojiani AM, et al. Monomorphous angiocentric glioma: A distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma. J Neuropathol Exp Neurol. 2005;64:875-881.
54. Lellouch-Tubiana A, Boddaert N, Bourgeois M, et al. Angiocentric neuroepithelial tumor (ANET): a new epilepsyrelated clinicopathological entity with distinctive MRI. Brain Pathol. 2005;15:281-286.
55. Preusser M, Hoischen A, Novak K, et al. Angiocentric glioma: Report of clinico-pathologic and genetic findings in 8 cases. Am J Surg Pathol. 2007;31:1709-1718.
56. Brat DJ, Scheithauer BW, Staugaitis SM, et al. Third ventricular chordoid glioma: a distinct clinicopathologic entity. J Neuropathol Exp Neurol. 1998;57:283-290.
57. Leeds NE, Lang FF, Ribalta T, et al. Origin of chordoid glioma of the third ventricle. Arch Pathol Lab Med. 2006;130: 460-464.
58. Horbinski C, Dacic S, McLendon RE. Chordoid glioma: a case report and molecular characterization of five cases. Brain Pathol. 2009;19:439-448.
59. Yip S, Iafrate JA, Louis DN. Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers. J Neuropathol Exp Neurol. 2008;67:1-15.
60. Colman H, Aldape K. Molecular predictors in glioblastoma. Toward personalized therapy. Arch Neurol. 2008;65:877-883.
61. Purow B, Schiff D. Advances in genetics of glioblastoma: are we reaching a critical mass? Nature Rev Neurol. 2009;5: 419-426.
62. Aldape K, Burger PC, Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med. 2007;131:242-251.
63. McDonald JM, See SJ, Tremont IW, et al. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer. 2005;104:1468-1477.
64. Perry A, Fuller CE, Banerjee R, et al. Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. Front Biosci. 2003;8: a1-a9.
65. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-1479.
66. Cairncross G, Berkey B, Shaw E. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707-2714.
67. Kanamori M, Kumabe T, Sonoda Y, et al. Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors. J Neurooncol. 2009;93:219-228.
68. Gianinni C, Burger PC, Berkey BA, et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol. 2008;18:360-369.
69. Griffin CA, Burger P, Morsberger BA, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q Loss. J Neuropathol Exp Neurol. 2006;65:988-994.
70. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66:9852-9861.
71. Kreiger PA, Okada Y, Simon S, et al. Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas. Acta Neuropathol. 2005;109:387-392.
72. Raghavan R, Balani J, Perry A, et al. Pediatric oligodendrogliomas: a study of molecular alterations on 1p and 19q using fluorescence in situ hybridization. J Neuropathol Exp Neurol. 2003;62:530-537.
73. Okamoto Y, DiPatre PL, Burkhard C, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 2004;108:49-56.
74. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl JMed. 2005;352:997-1003.
75. Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26: 4189-4199.
76. Brandes AA, Tosoni A, Franceschi E, et al., Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol. 2009;27:1275-1279.
77. Van den Bent MJ, Dubbink HJ, Sanson M, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2009;27:5881-5886.
78. Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010;6:39-51.
79. Rodriguez FJ, Thibodeau SN, Jenkins RB, et al. MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol. 2008;16:59-65.
80. Preusser M, Janzer RC, Felsberg J, et al. Anti-O6-methylguanine- methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol. 2008;18:520-532.
81. Sasai K, Nodagashira M, Nishihara H, et al. Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase (MGMT) status in glioma: relationship between immunohistochemistry and methylation analysis. Am J Surg Pathol. 2008;32:1220-1227.
82. Parkinson JF, Wheeler HR, Clarkson A, et al. Variation of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol. 2008;87:71-78.
83. Thon N, Eigenbrod S, Grasbon-Frodl EM, et al. Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas. J Neuropathol Exp Neurol. 2009;68:1219-1228.
84. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
85. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012-2024.
86. Pellowski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol. 2007;25:2288-2294.
87. Heimberger AB, Sampson JH. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther. 2009;9:1087-1098.
88. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009;324:261-265.
89. Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003;63:1602-1607.
90. Rich JN, Hans C, Jones B, et al. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res. 2005;65: 4051-4058.
91. Freije WA, Castro-Vargas FE, Fang Z, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004;64:6503-6510.
92. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157-173.
93. Colman H, Zhang L, Sulman EP, et al. A multigene predictor of outcome in glioblastoma. Neuro-Oncology. 2010;12: 49-57.
94. Verhaak RGW, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH-1, EGFR, and NF1. Cancer Cell. 2010;17:98-110.
95. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756-760.
96. Gunther HS, Schmidt NO, Phillips HS, et al. Glioblastomaderived stem cell-enriched cultures from distinct subgroups according to molecular and phenotypic criteria. Oncogene. 2008;27: 2897-2909.